09:51 AM EST - Protox Therapeutics Inc. : announced that it has completed dosing of the second cohort of patients in its previously announced transrectal study of PRX302 for the treatment of benign prostatic hyperplasia. Protox Therapeutics Inc.
shares T.PRX are trading even at $0.31.
